{"id":"mab-nimotuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:10:24.018414","_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling that drives cell growth and division. This antibody-mediated blockade leads to reduced proliferation, increased apoptosis, and enhanced radiosensitivity in EGFR-expressing tumors. Unlike some other anti-EGFR agents, nimotuzumab has a lower incidence of severe skin toxicity.","oneSentence":"Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:59.282Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT07446270","phase":"PHASE2","title":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-03","conditions":"Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer","enrollment":90},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT06771596","phase":"PHASE2","title":"Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":43},{"nctId":"NCT03025958","phase":"PHASE2","title":"Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2017-03-13","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT06259721","phase":"PHASE2","title":"Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2024-02-10","conditions":"Nasopharyngeal Carcinoma","enrollment":22},{"nctId":"NCT03620032","phase":"PHASE2","title":"Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2015-11-02","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":54},{"nctId":"NCT00702481","phase":"PHASE2","title":"Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2008-04-28","conditions":"Head and Neck Cancer","enrollment":32},{"nctId":"NCT04508816","phase":"PHASE2","title":"Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":45},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT04678791","phase":"NA","title":"Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-12","conditions":"Cervical Squamous Cell Carcinoma","enrollment":286},{"nctId":"NCT03469531","phase":"PHASE2","title":"Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2018-03-20","conditions":"Neoplasms, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma in Situ","enrollment":100},{"nctId":"NCT00561990","phase":"PHASE2, PHASE3","title":"Nimotuzumab in Adults With Pancreatic Cancer","status":"COMPLETED","sponsor":"Oncoscience AG","startDate":"2007-09","conditions":"Pancreatic Cancer, Advanced or Metastatic","enrollment":188},{"nctId":"NCT02095119","phase":"PHASE1, PHASE2","title":"A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2008-07","conditions":"Uterine Cervical Cancer","enrollment":15},{"nctId":"NCT02083211","phase":"PHASE3","title":"Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2010-07","conditions":"Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment","enrollment":168},{"nctId":"NCT00561691","phase":"","title":"Nimotuzumab in Children With Intrinsic Pontine Glioma","status":"COMPLETED","sponsor":"Oncoscience AG","startDate":"2006-04","conditions":"Diffuse Instrinsic Ponitine Glioma","enrollment":41},{"nctId":"NCT00753246","phase":"PHASE3","title":"Nimotuzumab in Adults With Glioblastoma Multiforma","status":"COMPLETED","sponsor":"Oncoscience AG","startDate":"2007-08","conditions":"Adults With Glioblastoma Multiforma","enrollment":150},{"nctId":"NCT00600054","phase":"PHASE2","title":"Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma","status":"COMPLETED","sponsor":"YM BioSciences","startDate":"2007-10","conditions":"Recurrent Diffuse Pontine Gliomas","enrollment":44},{"nctId":"NCT00493857","phase":"PHASE2","title":"Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"YM BioSciences","startDate":"2007-06","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT00369252","phase":"PHASE1","title":"Phase I Study of Nimotuzumab in Solid Tumours","status":"COMPLETED","sponsor":"YM BioSciences","startDate":"2005-06","conditions":"Advanced and/or Metastatic Solid Tumours","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mAb Nimotuzumab","genericName":"mAb Nimotuzumab","companyName":"National Institute of Cancerología","companyId":"national-institute-of-cancerolog-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}